Immunotherapy in castration-resistant prostate cancer: Integrating sipuleucel-T into our current treatment paradigm

Oncology

Volumn 25, Issue 3, 2011, Pages

  Garcia, Jorge A ^a,b   Dreicer, Robert ^a,b  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CANCER VACCINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DNA VACCINE; DOCETAXEL; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; IPILIMUMAB; PLACEBO; PREDNISONE; PROSTVAC; PROVENGE; UNCLASSIFIED DRUG; VIRUS VECTOR;

BACKACHE; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CEREBROVASCULAR ACCIDENT; CHILL; DIARRHEA; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; FATIGUE; FEVER; FLU LIKE SYNDROME; FOWLPOX VIRUS; HEADACHE; HUMAN; HYPERHIDROSIS; HYPERTENSION; HYPOKALEMIA; HYPOPITUITARISM; INJECTION SITE REACTION; MUSCLE WEAKNESS; MYALGIA; NAUSEA; NONHUMAN; OVERALL SURVIVAL; PAIN; PROSTATE CANCER; PRURITUS; RASH; REVIEW; SINGLE DRUG DOSE; TEMPORAL ARTERITIS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VACCINIA VIRUS; VIRAL GENE DELIVERY SYSTEM;

EID: 79953099043     PISSN: 08909091     EISSN: 08909091     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300
2. Oh WK, Kantoff PW. Management of hormone refractory prostate cancer: Current standards and future prospects. J Urol. 1998;1160:1220-9. (Pubitemid 29480485)
3. Chi KN, Bjartell A, Dearnaley D, et al. Castration-resistant prostate cancer: from new pathophysiology to new treatment targets. Eur Urol. 2009;56:594-605.
4. Coffey DS, Isaacs JT. Control of prostate growth. Urology. 1981;17:17-24. (Pubitemid 11110409)
5. Wang X, Yu J, Sreekumar A, et al. Autoantibody signatures in prostate cancer. N Engl J Med. 2005;353:1224-35. (Pubitemid 41345944)
6. Taylor BS, Varambally S, Chinnaiyan AM. Differential proteomic alterations between localized and metastatic prostate cancer. Br J Cancer. 2006;95:425-30. (Pubitemid 44232549)
7. Rhodes DR, Barrette TR, Rubin MA, et al. Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. Cancer Res. 2002;62:4427-33. (Pubitemid 34827303)
8. Antonarakis ES, Drake CG. Current status of immunological therapies for prostate cancer. Curr Opin Urol. 2010;20:241-6.
9. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol. 1991;9:271-96.
10. Lieschke GJ, Burgess AW. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. N Engl J Med. 1992;372:28-35.
11. Nelson WG, Simons JW, Mikhak B, et al. Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies. Cancer Chemother Pharmaco. 2000;46 Suppl: S567-72.
12. Simons JW, Mikhak B, Chang JF, et al. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res. 1999;59:5160-8. (Pubitemid 29503977)
13. Simons JW, Small ES, Nelson W, et al. Phase II trials of a GM-CSF gene-transduced prostate cancer cell line vaccine (GVAX) demonstrate anti-tumor activity. Program/Proceedings of the American Society of Clinical Oncology. 2001;20:175b (abstract 1073).
14. Small EJ, Reese D, Um B, et al. Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor. Clin Cancer Res. 1999;5:1738-44. (Pubitemid 29334454)
15. Rini BI, Weinberg V, Bok R, et al. Prostate-specific antigen kinetics as a measure of the biologic effect of granulocyte macrophage colony-stimulating factor in patients with serologic progression of prostate cancer. J Clin Oncol. 2003;21:99-105.
16. Dreicer R, See WA, Klein EA, Phase II trial of GM-CSF in advanced prostate cancer. Invest New Drugs. 2001;19:261-65. (Pubitemid 32781207)
17. Krummel MF, Allison JP. CTL A-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med. 1996;183:2533-40. (Pubitemid 26192363)
18. Greenwald RJ, Boussiotis VA, Lorsbach RB, et al. CT LA-4 regulates induction of anergy in vivo. Immunity. 2001;14:145-55. (Pubitemid 32206517)
19. Egen JG, Kuhns MS, Allison JP. CTL A-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol. 2002;3:611-8. (Pubitemid 34752469)
20. Thompson CB, Allison JP. The emerging role of CTLA-4 as an immune attenuator. Immunity. 1994;7:445-50.
21. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996;271:1734-6. (Pubitemid 26102823)
22. Van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte-macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med. 1999;190:355-66. (Pubitemid 29374833)
23. Small EJ, Tchekmedyian NS, Rini BI, et al. A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res. 2007;13:1810-5. (Pubitemid 46952950)
24. Fong L, Kwek SS, OBrien S, et al. Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA-4 blockade and GM-CSF. Cancer Res. 2009;2:609-615.
25. Ribas A, Hauschild A, Kefford R, et al. Phase III, open label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma. J Clin Oncol. 2008;26:9011.
26. Hodi FS, ODay SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711-23.
27. Johnson LE, Frye TP, Chinnasamy N, et al. Plasmid DNA vaccine encoding prostatic acid phosphatase (PAP) is effective in eliciting autologous antigen-specific CD8+ T cells. Canc Immunol Immunoth. 2007;56:885-95. (Pubitemid 46723588)
28. Johnson LE, Frye TP, Arnot AR, et al. Safety and immunological efficacy of a prostate cancer plasmid DNA vaccine encoding prostatic acid phosphatase (PAP). Vaccine. 2006;3:293-303. (Pubitemid 41790433)
29. McNeel DG, Dunphy EJ, Davies JG, et al. Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer. J Clin Oncol. 2009;25:4047-54.
30. Eder JP, Kantoff PW, Roper K, et al. A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin Cancer Res. 2000;6:1632-8. (Pubitemid 30305054)
31. Hodge JW, Schlom J, Donohue SJ, et al. A recombinant vaccinia virus expressing human prostate-specific antigen (PSA): safety and immunogenicity in a non-human primate. Int J Cancer. 1995;63:231-7.
32. Gulley J, Chen AP, Dahut W, et al. Phase 1 study of vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer. Prostate. 2002;53:109-17.
33. Kaufman HL, Wang W, Manola J, et al: Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2004;22:2122-32.
34. DiPaola RS, Plante M, Kaufman H, et al. A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer. J Transl Med. 2006;4:1-5.
35. Arlen PM, Skarupa L, Pazdur M, et al. Clinical safety of a viral vector based prostate cancer vaccine strategy. J Urol 2007;178:1515-1520. (Pubitemid 47368382)
36. Kantoff PW, Schuetz TJ, Blumenstein BA, et al. Overall survival analysis of a phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol. 2010;28:1099-1105.
37. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granuloctye-macrophage colony-stimulating factor stimulates potent, specific, and long lasting anti-tumor immunity. Proc Natl Acad Sci. 1993;90:3539-43. (Pubitemid 23111402)
38. Jaffee EM, Lazenby A, MeuerJ, et al. Use of murine models of cytokine-secreting tumor vaccines to study feasibility and toxicity issues critical to designing clinical trials. J Immunother Emphasis Tumor Immunol. 1995;18:1-9.
39. Simons JW, Mikhak B, Chang JF, et al. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res. 1999;59:5160-8. (Pubitemid 29503977)
40. Simons JW, Carducci MA, Mikhak B, et al. Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naive prostate cancer. Clin Cancer Res. 2006;12:3394-401.
41. Small EJ, Sacks N, Nemunaitis J, et al. Granulocyte macrophage colony-stimulating factor-secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin Cancer Res. 2007;13:3883-91. (Pubitemid 47037595)
42. Higano CS, Corman JM, Smith DC, et al. Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. Cancer. 2008;5:975-84.
43. Halabi S, Small EJ, Kantoff PW, et al. Prognostic model for predicting survival in men with HRPC. J Clin Oncol. 2003;21:1232-7.
44. Higano C, Saad F, Somer B, et al. A phase III trial of GVAX immunotherapy for prostate cancer versus docetaxel plus prednisone in asymptomatic, castration-resistant prostate cancer (CRPC). 2009 ASCO GU Meeting. Abstract LBA150.
45. Haines AM, Larkin SE, Richardson AP, et al. A novel hybridoma antibody (PASE/4LJ) to human prostatic acid phosphatase suitable for immunohistochemistry. Br J Cancer. 1989;60:887-92. (Pubitemid 20024181)
46. Goldstein NS. Immunophenotypic characterization of 225 prostate adenocarcinomas with intermediate or high Gleason scores. Am J Clin Pathol. 2002;117:471-7. (Pubitemid 34226085)
47. Small EJ, Fratesi P, Reese DM, et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. Clin Oncol. 2000;23:3894-903.
48. Burch PA, Croghan GA, Gastineau DA, et al. Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a phase 2 trial. Prostate. 2004;3:197-204. (Pubitemid 38971831)
49. Beinart G, Rini BI, Weinberg V, Small EJ. Antigen-presenting cells 8015 (Provenge) in patients with androgen-dependent, biochemically relapsed prostate cancer. Clin Prostate Cancer. 2005;1:55-60. (Pubitemid 41018184)
50. Rini BI, Weinberg V, Fong L, et al. Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (Provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy. Cancer. 2006;1:67-74. (Pubitemid 43939032)
51. Small EJ, Schellhammer PF, Higano CS, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol. 2006;19:3089-94. (Pubitemid 46638945)
52. Higano CS, Schellhammer PF, Small EJ, et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer. 2009;16:3670-9.
53. Kantoff PW, Higano CS, Shore ND, et al, for the IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411-22
54. Smaletz O, Scher HI, Small EJ, et al. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol. 2002;19:3972-82.
55. Halabi S, Small EJ, Kantoff PW, et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol. 2003;7:1232-7. (Pubitemid 46606398)
56. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;9747:1147-54.
57. De Bono JS, Logothetis C, Fizazi K, et al. Abiraterone acetate plus low dose prednisone improves overall survival in patients with metastatic castration-resistant prostate cancer (CRPC) who have progressed after docetaxel-based chemotherapy: results of COU-AA-301, a randomized double-blind placebo-controlled phase 3 study. Abstract LBA5; ESMO 2010.